Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 6 de 6
Filtre
1.
Rev. bras. hematol. hemoter ; 34(6): 447-451, 2012. ilus
Article Dans Anglais | LILACS | ID: lil-662722

Résumé

Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year. At Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - HCFMUSP, diffuse large B-Cell lymphoma represents 49.7% of all non-Hodgkin lymphoma cases. Initially, the classification of non-Hodgkin lymphoma was based on morphology, but advances in immunology and molecular medicine allowed the introduction of a biological classification for these diseases. As for other cancers, non-Hodgkin lymphoma involves patterns of multi factorial pathogenesis with environmental factors, as well as genetic, occupational and dietary factors, contributing to its development. Multiple lesions involving molecular pathways of B-cell proliferation and differentiation may result in the activation of oncogenes such as the BCL2, BCL6,and MYC genes and the inactivation of tumor suppressor genes such as p53 and INK4, as well as other important transcription factors such as OCT-1 and OCT-2. A dramatic improvement in survival was seen after the recent introduction of the anti-CD20 monoclonal antibody. The association of this antibody to the cyclophosphamide, hydroxydaunorubicin, oncovin and prednisolone (CHOP) regimen has increased overall survival of diffuse large B-Cell lymphoma and follicular lymphoma patients by 20%. However, 50% of all diffuse large B-Cell lymphoma patients remain incurable, creating a demand for more research with new advances in treatment. Thus, it is important to know and understand the key factors and molecular pathways involved in the pathogenesis of diffuse large B-Cell lymphoma.


Sujets)
Humains , Gènes suppresseurs de tumeur , Lymphomes , Lymphome B/physiopathologie , Oncogènes , Pronostic
2.
Article Dans Anglais | IMSEAR | ID: sea-39664

Résumé

BACKGROUND: High frequency of Epstein-Barr virus (EBV) in the normal mucosa of the upper aerodigestive tract suggests that it may serve as a reservoir for the virus. Malignant lymphomas arising in this site may be associated with EBV. OBJECTIVES: To determine the prevalence of EBV infection in extranodal malignant lymphomas of the upper aerodigestive tract. SETTING: King Chulalongkorn Memorial Hospital, Thailand. DESIGN: Descriptive study. PATIENTS: 42 Thai patients who presented between 1998 and 2003. MATERIAL AND METHOD: The expression of EBV mRNAs (EBERs) of malignant lymphoma was studied by means of in situ hybridization in formalin-fixed, paraffin-embedded specimens. RESULTS: The recruited subjects were 26 males and 16 females, and their age ranged from 3 to 85 years with the mean of 51.43 years, in 4 of them human immune deficiency virus (HIV) infection was documented. Ten of 42 cases (23.81%) expressed EBER transcripts and were extranodal NK/T-cell lymphomas, nasal type (7 cases), plasmablastic lymphomas (2 cases) and diffuse large B-cell lymphoma (1 case). Three of 4 cases (75%) of known HIV-seropositive cases were EBV-positive (2 plasmablastic lymphomas and 1 diffuse large B-cell lymphoma). CONCLUSION: In the upper aerodigestive tract, EBV was present in some but not all malignant lymphoma. It was associated with extranodal NK/T-cell lymphoma, nasal type and B-cell lymphoma arising in HIV-infected patients, but it was not found in B-cell lymphoma arising in immunocompetent patients.


Sujets)
Adolescent , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Enfant , Enfant d'âge préscolaire , Réservoirs de maladies , Infections à virus Epstein-Barr/épidémiologie , Femelle , Herpèsvirus humain de type 4/isolement et purification , Humains , Hybridation in situ , Lymphomes/physiopathologie , Lymphome B/physiopathologie , Lymphome T/physiopathologie , Mâle , Adulte d'âge moyen , Prévalence , Appareil respiratoire/physiopathologie , Facteurs de risque , Thaïlande/épidémiologie , Tube digestif supérieur/physiopathologie
4.
Rev. méd. Hosp. Gen. Méx ; 61(1): 41-6, ene.-mar. 1998. ilus
Article Dans Espagnol | LILACS | ID: lil-240934

Résumé

Los linfomas primarios del intestino delgado son tumores raros, ocupan del 20 al 40 por ciento de las neoplasias malignas de esa región. Son un grupo heterogéneo de tumores con características clínicas y patológicas variables. Son neoplasias de adultos, se presentan con mayor frecuencia de los 20 a los 60 años. Los síntomas se desarrollan insidiosamente y pueden incluir pérdida de peso, diarrea, sangrado rectal, dolor abdominal, vómito y constipación. La enfermedad celiaca, la enfermedad inflamatoria intestinal y los estados de inmunodeficiencia se consideran factores predisponentes. El comportamiento biológico, el cuadro clínico, la morfología, el inmunofenotipo y el tratamiento son diferentes de los de los linfomas originados en ganglios linfáticos. Para clasificarlos correctamente es necesario definir el tipo histológico, el grado histológico, la resecabilidad del tumor y si se logra o no la remisión después del tratamiento combinado


Sujets)
Humains , Mâle , Femelle , Enfant d'âge préscolaire , Adolescent , Adulte , Adulte d'âge moyen , Maladie immunoproliférative de l'intestin grêle/anatomopathologie , Lymphome B/physiopathologie , Lymphome B/anatomopathologie , Lymphome T/physiopathologie , Lymphome T/anatomopathologie , Lymphome T/thérapie , Lymphome de Burkitt/physiopathologie , Lymphome de Burkitt/anatomopathologie , Lymphome de Burkitt/thérapie , Survivants , Tumeurs de l'intestin/diagnostic , Tumeurs de l'intestin/physiopathologie , Tumeurs de l'intestin/anatomopathologie , Tumeurs de l'intestin/thérapie , Intestin grêle/anatomopathologie , Lymphomes/classification , Stadification tumorale/effets indésirables , Pronostic
5.
Bol. Soc. Bras. Hematol. Hemoter ; 17(168): 15-8, jan.-abr. 1995.
Article Dans Anglais | LILACS | ID: lil-194645

Résumé

There are few reports in the world medical literature concerning association between leprosy and malignant lymphoma. It seams that, although defects in immune system related to leprosy are multiple and complex, no increase in incidence of malignant lymphoma among leprosy patients can be detected. This is also true for Brazil, where leprosy is an endemic disease, which poses an important public health problem. For this reason, the authors report on three cases of malignant lymphoma: one low grade, B-cell lymphoma (immunocytoma): one high grade, T-cell lymphoma and one mixed cellularity Hodgkin's disease in patients previously diagnosed as having leprosy.


Sujets)
Humains , Mâle , Adulte , Adulte d'âge moyen , Lèpre/complications , Lymphomes/complications , Maladie de Hodgkin/complications , Maladie de Hodgkin/physiopathologie , Lèpre/physiopathologie , Lymphome B/complications , Lymphome B/physiopathologie , Lymphome T/complications , Lymphome T/physiopathologie , Lymphomes/physiopathologie
6.
Rev. invest. clín ; 44(3): 387-92, jul.-sept. 1992. ilus
Article Dans Anglais | LILACS | ID: lil-118280

Résumé

Este artículo describe el caso clínico de un enfermo con SIDA coinfectado por HTLV-1 que desarrolló un linfoma B del recto, variedad sarcoma inmunoblástico con diferenciación plasmacitoide. Las células malignas mostraron arreglo clonal de los genes de las CP (Jh) y CLk. La infección por el VEB fue demostrada serológicamente y por hibridación de un monitor específico con el ADN genómico de las células cancerosas. No se detectaron secuencias de HTLV-1 en el seno del tumor. Una remisión clínica completa, pero temporal, se obtuvo con siete ciclos de VACO-B. El enfermo abandonó el tratamiento y la sobrevida se desconoce.


Sujets)
Humains , Mâle , Adulte d'âge moyen , Syndrome d'immunodéficience acquise , Cyclophosphamide/usage thérapeutique , Doxorubicine/usage thérapeutique , Association de médicaments , VIH-1 (Virus de l'Immunodéficience Humaine de type 1) , Virus T-lymphotrope humain de type 1 , Lymphome B/physiopathologie , Lymphome immunoblastique à grandes cellules/physiopathologie , Tumeurs du rectum/diagnostic , Tumeurs du rectum/étiologie , Vincristine/usage thérapeutique
SÉLECTION CITATIONS
Détails de la recherche